<DOC>
	<DOCNO>NCT02034604</DOCNO>
	<brief_summary>This study design evaluate efficacy safety naftopidil patient neurogenic low urinary tract dysfunction cause benign prostatic hyperplasia .</brief_summary>
	<brief_title>Efficacy Safety Naftopidil Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Naftopidil</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>1 . Male female age 20 year old ( upper limit age : 80 year old ) 2. patient diagnose neurogenic bladder due cerebrovascular accident , parkinson disease , spinal cord lesion , diabetic neuropathy etc ) 3. a+b 1 . IPSS ≥ 12 QoL ≥ 3 2 . Maximum Flow Rate &lt; 15 mL/s ( Voiding volume ) ≥ 120mL ) 4 . Ability willingness correctly complete micturition diary questionnaire 5 . Capable understanding sign informed consent form full discussion research nature treatment risk benefit 1 . In male age 50 year old , bladder outlet obstruction ( Bladder Outlet Obstruction Index ( BOOI ) ≥40 ) 2 . In female , Pelvic Organ Prolapse ICS stage ; POPQ stage ≥ 2 3 . In female , history antiincontinence operation . 4 . Patients cancer type include cancer prostate bladder 5 . Patients urethral stricture bladder neck contracture</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Naftopidil</keyword>
	<keyword>safety</keyword>
</DOC>